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Abstract
Osteosarcoma is an aggressive malignancy of the bone and an increase in serum alkaline phosphatase concentration has
clinical prognostic value in both humans and canines. Increased serum alkaline phosphatase concentration at the time of
diagnosis has been associated with poorer outcomes for osteosarcoma patients. The biology underlying this negative
prognostic factor is poorly understood. Given that activation of the Wnt signaling pathway has been associated with
alkaline phosphatase expression in osteoblasts, we hypothesized that the Wnt/b-catenin signaling pathway would be
differentially activated in osteosarcoma tissue based on serum ALP status. Archived canine osteosarcoma samples and
primary canine osteosarcoma cell lines were used to evaluate the status of Wnt/b-catenin signaling pathway activity
through immunohistochemical staining, western immunoblot analyses, quantitative reverse-transcription polymerase chain
reaction, and a Wnt-responsive promoter activity assay. We found no significant difference in b-catenin expression or
activation between OSA populations differing in serum ALP concentration. Pathway activity was mildly increased in the
primary OSA cell line generated from a patient with increased serum ALP compared to the normal serum ALP OSA cell line.
Further investigation into the mechanisms underlying differences in serum ALP concentration is necessary to improve our
understanding of the biological implications of this negative prognostic indicator.
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Introduction
Osteosarcoma (OSA) is the most common primary bone
malignancy of humans [1]. A notably aggressive disease, relapse
and/or metastasis occurs in 80% of cases [2]. Five-year survival
rates are approximately 80% with localized disease, but survival
rate drops to roughly 30% if metastatic lesions are present [3].
Naturally occurring canine osteosarcoma is an accepted, clinically
relevant animal model of human osteosarcoma; the diseases are
indistinguishable grossly [3,4] and biochemically [5]. Similar to
the human disease, osteosarcoma accounts for 85–98% of all
canine bone tumors [6,7]; and pulmonary metastasis occurs in
90% of cases following removal of the primary tumor [7,8]. As
previously stated, the disease similarities between the two species
have made canine osteosarcoma a valuable model for human
osteosarcoma. Of additional value is the higher incidence and the
accelerated biology of canine osteosarcoma compared to human
osteosarcoma [5,7]. The use of canine osteosarcoma as a
comparative model allows for faster accrual of samples and
performance of pre-clinical trials, with the intent to improve
outcomes for both humans and canines. A better understanding of
osteosarcoma is necessary, as despite advances in treatment
regimens, the median survival time for either humans or dogs
with osteosarcoma has not changed drastically in the last 10–20
years [1–3,9]. In both species, prognosis worsens with increased
serum alkaline phosphatase (ALP) concentration, correlating with
shorter survival and disease-free intervals [10–13].
The expression of ALP is frequently used to identify cells of the
osteoblastic lineage and is a hallmark of osteoblastic activity.
Studies have suggested that ALP is a transcriptional target of the
Wnt/b-catenin signaling pathway, as activation of this pathway in
osteoblasts has been associated with increased ALP expression
[14,15]. When Wnt signaling is active, b-catenin accumulates
within the cytoplasm, translocates to the cell nucleus, and
associates with members of the TCF/LEF transcription factor
family leading to transcription of target genes, including ALP [16].
The Wnt/b-catenin signaling pathway is crucial for normal bone
development and its transient activation is required for mesenchy-
mal stem cell (MSC) commitment to the osteoblastic lineage [17].
MSCs have been identified as a potential cell of origin in OSA
development [18], and alterations in pathways involved in normal
bone development may be implicated in OSA pathogenesis.
However, details of the role Wnt/b-catenin signaling may play in
OSA development have yet to be clarified. Support for activation of
the Wnt/b-catenin pathway in OSA include the findings that
nuclear and cytoplasmic b-catenin staining is present in human
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b-catenin expression in tissue from xenogeneic murine pulmonary
metastasis [20]; and that tumorigenesis is decreased with inhibition
of Wnt receptors [21,22]. However, some report that the Wnt/b-
catenin pathway is selected against in OSA development: loss of
Wnt/b-catenin signaling was found to contribute towards OSA
development [23]; and inhibition of Wnt/b-catenin signaling has
been shown to transform human MSCs [24].
Few studies have investigated the extent of active Wnt/b-
catenin signaling in canine OSA, and no studies address
specifically the potential role b-catenin may have in the increased
serum ALP phenotype. As a prognostic indicator, serum ALP is
aligned with poor outcome, and understanding the mechanism
behind this phenomenon will allow us to better understand the
biological relevance of altered serum ALP concentrations in OSA
pathogenesis. This insight can be used for future clinical and
therapeutic interventions for both humans and animals.
Our overarching aim within this study was to determine if Wnt/
b-catenin signaling is differentially activated in OSA tissue from
dogs with increased serum ALP concentration. We achieved this
by: (a) determining if b-catenin is differentially expressed, with
respect to both quantity and cellular localization, between canine
OSA patient populations with increased and normal serum ALP
concentrations; and (b) determining if cell lines derived from
normal and increased serum ALP OSA tissue have differential b-
catenin activity as determined by: (i) the nuclear localization of b-
catenin, and (ii) TCF binding site reporter plasmid activity. We
hypothesized that the increased serum ALP levels associated with
some canine OSA populations would be due to increased Wnt/b-
catenin pathway activity.
Results
Evaluation of Wnt/b-catenin signaling pathway in OSA
samples from patients with normal and increased serum
ALP concentration using qPCR
Our first aim was to determine if b-catenin mRNA was
differentially expressed in OSA tumor tissue from dogs with
increased serum ALP concentration (n=10) compared to OSA
tumor tissue from dogs with normal serum ALP concentration
(n=9). The assignment of a patient to the increased serum ALP
concentration group was based on the patient’s serum ALP
concentration being above the upper limit of normal as defined by
the reporting institute (see Materials & Methods). The median
ALP concentration for dogs with increased serum ALP that had
tissue available for assessment of mRNA expression was 212 U/L
(sample range: 144–733 U/L), compared to 104 U/L (sample
range: 45–218 U/L) (p,0.01) for dogs with normal serum ALP.
All tumor tissue mRNA was normalized to mRNA expression in
normal bone tissue from a patient without OSA. There was no
difference in the relative expression of b-catenin mRNA in tumor
samples from dogs with increased serum ALP concentration
compared to tumor samples from dogs with normal serum ALP
concentration (Figure 1A).
Figure 1A-C. Evaluation of Wnt/b-catenin pathway using QPCR. (A) Relative expression of b-catenin mRNA in two canine OSA populations:
increased serum ALP concentration (median =0.04, range =0.02–0.23) and normal serum ALP concentration (0.07, 0.02–0.15)(p=0.40). (B) Relative
expression of Wnt/b-catenin pathway downstream target gene Axin2 mRNA in increased serum ALP concentration (0.19, 0.08–0.35) and normal
serum ALP concentration (0.20, 0.11–1.11)(p=0.32). (C) Relative expression of Wnt/b-catenin pathway downstream target gene Sox9 mRNA in
increased serum ALP concentration (0.87, 0.03–16.72) and normal serum ALP concentration (1.80, 0.20–17.24)(p=0.24). All expression values are
normalized to 18S expression and to normal, non-OSA canine bone. Comparisons made using two-tailed Mann-Whitney t-test.
doi:10.1371/journal.pone.0026106.g001
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expression of downstream targets of the Wnt/b-catenin signaling
pathway between OSA tissue from dogs with increased serum ALP
concentration and those with normal serum ALP concentration.
Again, qPCR was used to assess relative mRNA expressionof Axin2
andSox9,twodownstreamtargets ofWnt/b-cateninactivity.Axin2
gene expression is positively regulated by active Wnt/b-catenin
signaling therefore an increase in Axin2 expression would be
expected with active Wnt/b-catenin signaling. Conversely, Sox9
gene expression is negatively regulated by Wnt/b-catenin activity
and a reduction in Sox9 gene expression would be expected with
active Wnt/b-catenin signaling. Consistent with the lack of
difference in relative expression of b-catenin mRNA between the
two populations, no difference was found in the relative expression
of Axin2 or Sox9 in tumor tissue associated with increased serum
ALP concentration compared to normal serum ALP concentration
(Figure 1B&C). Additionally, we assessed target gene expression as a
continuous function of serum ALP value (non-pooled, individual
analysis). For all target genes, expression did not correlate with
serum ALP (b-catenin: R
2=0.02, p=0.61; Axin2: R
2=0.02,
p=0.63; Sox9: R
2=0.01, p=0.70; data not shown).
Western blot of tissue lysates from patients with normal
or increased serum ALP concentration
As b-catenin is highly regulated post-translationally, protein
expression of pooled tissue lysates from patients with normal
(n=5) and increased (n=5) serum ALP concentration was
assessed to confirm the mRNA expression data. Samples used
for tissue lysates were a randomly chosen sub-population of those
used for qPCR analysis. b-catenin was identified in the lysates
from both patient populations. There was no difference in the b-
catenin expression of the normal serum ALP lysate compared to
the increased serum ALP lysate (Figure 2A).
Western blot of the nuclear fraction of an increased
serum ALP canine OSA cell line and a normal serum ALP
canine OSA cell line derived from patient tissue
To assess the nuclear translocation of b-catenin between the two
patient populations, western blot analysis was performed on the
nuclear fraction of cell lysate from a single primary cell line
derived from either increased serum ALP concentration patient
tissue (iALPOS; serum total ALP 388 U/L, reference range: 20–
157 U/L) and normal serum ALP concentration patient tissue
(nALPOS; serum total ALP 124 U/L, reference range: 13–
289 U/L). The nuclear fraction lysate from the iALPOS cell line
displayed a slight decrease in b-catenin expression compared to
the nALPOS cell line (Figure 2B).
Luciferase Reporter Assay to determine Wnt/b-catenin
pathway activity
Both the downstream gene target qPCR and the western blot of
the nuclear fraction indicate that the Wnt/b-catenin pathway is
not differentially activated in patients with increased serum ALP;
to further confirm this data, a TCF-responsive luciferase reporter
assay was performed. b-catenin acts as a transcriptional co-factor
and binds to members of the TCF/LEF transcription factor family
(reviewed in 25) resulting in expression of genes downstream of the
TCF sites. In the TOPflash plasmid, luciferase is downstream of
several TCF sites, thus increased Wnt/b-catenin activity would be
indicated by higher luciferase expression, or a higher TOP/FOP
ratio. The iALPOS cell line was found to have a higher TOP/
FOP ratio (2.0560.17; mean 6 SEM) compared to the nALPOS
cell line (1.4760.05; p,0.01, unpaired two-tailed t-test) (Figure 3).
Immunohistochemistry for expression of b-catenin in
tissue samples from patients with normal and increased
serum ALP
Given the apparent lack of differential expression or pathway
activity in the small number of frozen samples and cell lines, a
larger group of patients was used to confirm these findings.
Immunohistochemistry was performed to detect b-catenin expres-
sion and localization in tumor tissue from patients with a known
serum ALP status. As discussed above, serum ALP concentrations
were determined at multiple institutions resulting in differing
reference ranges. To account for differences in reference ranges,
Figure 2. Western blot analysis of b-catenin protein expression.
(A) Presence of b-catenin in canine osteosarcoma tissue lysate pooled
from patients with increased (n=5) or normal (n=5) serum ALP
concentration. Lysates were derived from a sub-population of patients
used in the QPCR study. (B) Presence of b-catenin in nuclear lysate from
canine osteosarcoma cell lines derived from a single patient with either
increased (iALPOS) or normal (nALPOS) serum ALP concentration.
GAPDH was used as a total cell lysate loading control (2A), and Laminin
was used as a nuclear marker for loading control (2B).
doi:10.1371/journal.pone.0026106.g002
Figure 3. Luciferase Reporter Assay to assess Wnt/b-catenin
pathway activity in osteosarcoma cell lines associated with
increased (iALPOS) or normal (nALPOS) serum ALP concentra-
tion. TOPflash and FOPflash values are corrected to respective Renilla
luminescence as a transfection control. iALPOS TOP/FOPflash
(2.0560.17, mean 6 SEM) compared to nALPOS TOP/FOPflash
(1.4760.05) (p,0.01 using unpaired two-tailed t-test).
doi:10.1371/journal.pone.0026106.g003
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group based on being above the upper limit of normal for the
reporting institute’s reference range (see Materials & Methods).
The median serum ALP concentration for dogs with normal ALP
was 78 U/L (n=32, sample range: 34–217 U/L) compared to
330 U/L (n=24, sample range: 131-.1000 U/L) for dogs with
increased ALP. There was no difference in the overall b-catenin
staining score between the two populations, nor was there any
difference in the subcellular distribution of b-catenin staining
between the two populations (Table 1, Figure 4).
Discussion
Osteosarcoma is a notably aggressive disease, and as such,
prognostic indicators are extremely useful in the clinical setting.
Serum alkaline phosphatase (ALP) concentration has been
correlated with overall survival times and disease-free intervals,
and an increased serum ALP concentration is a negative
prognostic indicator for both human and canine OSA patients
[9–12]. However, the biological mechanism underlying the
increased concentration of serum ALP in this subpopulation of
OSA patients, both human and canine, has yet to be investigated.
Our intent with this study was to determine whether alterations in
the Wnt/b-catenin signaling pathway were part of the biological
mechanism underlying this negative prognostic factor utilizing
canine OSA as a comparative model for human OSA.
Cellular ALP is frequently used as a marker of osteoblasts and
its expression is increased during latter stages of osteoblastic
differentiation [26]. Similarly, the Wnt/b-catenin signaling
pathway is upregulated during osteoblast differentiation; in fact,
activation of the Wnt/b-catenin signaling pathway is essential for
mesenchymal stem cells to commit to the osteoblastic lineage [17].
Without Wnt pathway activation, these cells commit to either
adipogenic or chondrogenic lineages (reviewed in [16]). It is
further known that the promoter region of ALP contains TCF
binding sequences, which are the binding sites for b-catenin and
associated transcription factors [27]. Given these facts, we
hypothesized that the differences in serum ALP concentration
associated with some canine OSA patients was due to differential
activity in Wnt/b-catenin signaling pathway.
The major objective of this study was to determine if Wnt/b-
catenin signaling is enhanced in canine OSA tissue from patients
with increased serum ALP concentration compared to patients
with normal serum ALP concentration. To address this, b-catenin
expression was first examined at the mRNA level in frozen canine
OSA samples from patients with known serum ALP concentration.
No difference was found in the two patient populations at the
mRNA level. This indicates that transcription of the b-catenin
gene is not different between the two populations. However, b-
catenin expression is highly regulated at the post-translational level
and this may allow for differences to exist between the two
populations at the protein level [28,29].
Next, western immunoblots were performed on pooled tissue
lysates to assess if b-catenin is differentially regulated at the post-
translational level between the two populations, which would
result in altered total protein expression. Total b-catenin protein
expression was similar between pooled canine OSA tissue from
patients with normal or increased serum ALP. This indicates that
there are no differences in post-translational regulation of b-
catenin between the two tumor populations that would allow for
the stabilization of the protein and result in increased b-catenin
expression. Constitutive expression of b-catenin is a hallmark of
cancers noted for activated Wnt/b-catenin signaling, most notably
colorectal carcinomas and hepatocellular carcinomas (Reviewed in
[25,30]). These cancers typically have a mutation within b-catenin
itself or in one of the negative regulators of the pathway that
prevents the degradation of b-catenin. Most believe the true
indicator of pathway activation is denoted by the translocation of
b-catenin into the nucleus (reviewed in [16]). Thus it would be
possible that while the total cell quantity of b-catenin is similar
between patient samples, the localization of the protein may be
different, resulting in altered pathway activation.
Two methods were used to determine if the localization of b-
catenin differed between increased and normal serum ALP
samples: (i) western immunoblot of the nuclear fraction of cell
lysate from canine cell lines derived from either an increased
serum ALP patient (iALPOS) or a normal serum ALP patient
(nALPOS) and (ii) IHC of biopsies taken from canine patients of
known serum ALP concentration. There was a slight increase in b-
catenin in the nuclear fraction of the nALPOS cell line, though no
discernable differences were observed in nuclear b-catenin
expression as determined by IHC for these patient populations.
The lack of difference in protein localization between the
populations strongly suggests that Wnt/b-catenin pathway is not
differentially activated in canine patients with increased serum
ALP compared to normal serum ALP patients. However, neither
western blots nor IHC are particularly quantitative, and we
wanted to specifically determine the difference, if any, in pathway
activity between these two patient populations. This was done
using the TOPflash reporter assay, which is dependent upon the
binding of transcription factors to TCF-binding sites (TOPflash) to
drive luciferase expression. In this study there was a roughly 1.5-
Table 1. Characteristics of IHC staining for presence of b-catenin in canine OSA associated with increased or normal serum ALP
concentration.
Increased ALP OSA Normal ALP OSA
Median serum ALP concentration U/L (range)
a 330 (131-.1000) 78 (34–217)
Median overall b-catenin staining score (range)
b 3 (0–8) 6 (0–12)
Positive staining samples/total samples (%) 14/24 (58%) 22/32 (69%)
Membranous positive/total samples (%) 3/24 (13%) 9/32 (28%)
Cytoplasmic positive/total samples (%) 14/24 (58%) 21/32 (66%)
Nuclear positive/total samples (%) 1/24 (4%) 0/32 (0%)
aDifference in serum ALP concentration is significant using Mann-Whitney test (p,0.001).
bOverall b-catenin staining score is the product of percentage labelling score (0%=0, 1-,10%=1, 10–30%=2, .30–60%=3, .60%=4) and the staining intensity score
(negative =0, mild =1, moderate =2, intense =3).
doi:10.1371/journal.pone.0026106.t001
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canine OSA cell line (iALPOS) compared to the normal serum
ALP canine OSA cell line (nALPOS). While this value was
statistically significant, the clinical significance of this difference is
questionable, as there was no difference in downstream target
mRNA production (neither Axin2 nor Sox9). Cell lines with
mutations in the Wnt signaling pathway resulting in b-catenin
stabilization demonstrate significantly increased corrected lucifer-
ase TOP/FOPflash ratios: SW480, a human colon adenocarci-
noma cell line with a Wnt pathway activating mutation, has a
TOP/FOPflash ratio of 10 [23]; and Mel888, a human melanoma
cell line with a constitutively active b-catenin mutation, has a
TOP/FOPflash ratio of 12 (data not shown). Given the basally
active TOP/FOPflash ratios when compared to cell lines with
known Wnt pathway activating mutations, it seems unlikely that
activation of b-catenin is directly driving the differential expression
of serum ALP in canine OSA.
Our study indicates that increases in serum ALP associated with
some canine OSA patients is not due to differential Wnt/b-catenin
signaling activity between the two populations. However, these
finding are not meant to abandon the association of Wnt/b-
catenin signaling with ALP expression. Rather it is possible that
other intermediary signaling pathways, acting in concert with the
Wnt/b-catenin pathway, are differentially activated which may
amplify any Wnt/b-catenin activity. One such pathway that could
be involved is the BMP/Smad signaling pathway. In this model, b-
catenin prompts the expression of BMP4 and 6, which then
stimulate the activation of Smad1 and Smad5 in an autocrine/
paracrine fashion; this may result in differential ALP expression
and/or activity [31–34]. Alternatively, other pathways not
previously known to be associated with ALP regulation may be
involved. Currently, we are performing microarray analyses to
determine if other pathways are differentially activated between
these two patient populations.
It is possible the differences in ALP concentration may not be
due to differences at the transcriptional level. Rather, the differing
ALP concentrations may be due to differences in the post-
transcriptional or post-translational regulation of ALP, as it is well
established that ALP expression is regulated at many levels [26].
Two other possibilities as to why no differences in b-catenin
expression or activity were identified between the two canine OSA
populations is perhaps the increased serum ALP concentration was
not due to the bone isoform of ALP. A limitation of the current
study is the inability to verify the increased serum ALP
concentration was due the bone isoform of ALP. A number of
analyses were performed on archived tissue, both formalin-fixed
and frozen, and as such we were unable do perform iso-enzyme
analysis on serum collected concurrently. However, in the
selection of samples attempts were made to reduce the likelihood
that increased serum ALP was due to non-bone sources by
selecting only cases known to be free of corticosteroid treatment
pre-operatively and concurrent liver disease. Finally, some caution
must be exercised in regards to the ex vivo cell line results as only
two primary canine OSA cell lines were used. However, these cell
lines were used due to knowledge of the serum ALP status of the
patients from which they were generated. This information, to our
knowledge, is unavailable for most canine and human OSA cell
lines.
To the authors’ knowledge this is the first study investigating
possible cellular mechanisms responsible for the differential serum
ALP protein expression in canine OSA patient populations,
though no significant difference in b-catenin expression or activity
was found to exist between canine OSA samples associated with
normal and increased serum ALP concentration. Further
Figure 4A–C. Immunohistochemistry to assess b-catenin protein expression and localization. (A–B) Representative images of b-catenin
staining in OSA associated with increased (A) and normal (B) serum ALP concentration. (C) Photomicrograph of solitary sample with nuclear b-catenin
staining; arrow indicates example of cells positive for nuclear b-catenin staining. All photomicrographs images at 400x magnification.
doi:10.1371/journal.pone.0026106.g004
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ALP concentration are important to improving our understanding
of the biological implications of this negative prognostic indicator.
The identification of altered signaling pathways unique to this
negative prognostic factor may assist in developing therapeutic
interventions based on this knowledge and potentially improve
outcomes for this population of patients.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the UW-Madison’s School of
Veterinary Medicine Animal Care and Use Committee (Protocol:
V01391-0-09-08). Owner consent was obtained prior to the
collection of tumor tissue and generation of cell lines.
Clinical Sample Selection
For experiments involving immunohistochemistry, archived
tissue blocks of canine OSA associated with normal (n=32) and
increased (n=24) serum ALP from the Pathology Service at the
University of Wisconsin-Madison Veterinary Medical Teaching
Hospital (UWVMTH) were identified by medical records search.
Patient requirements for inclusion into this portion of the study
included no treatment with corticosteroids for a period of two
weeks preceding the identification of increased serum ALP
concentration and liver enzyme values within normal limits with
the exception of ALP. Canine OSA tissue was collected at the time
of diagnostic biopsy, surgical amputation or necropsy. One
investigator (AM) from the histopathology service reviewed all
slides to confirm the diagnosis of OSA.
For experiments involving RNA analysis, tumor tissue was
either collected from dogs at the UWVMTH or obtained from a
tumor bank at Colorado State University’s College of Veterinary
Medicine. All tumor tissue collected at the time of a diagnostic
biopsy or amputation for treatment of OSA was flash-frozen in
liquid nitrogen and stored at 280uC. All tumor tissue is from dogs
with known serum alkaline phosphatase concentration, drug
history, and histological confirmation of OSA. Frozen normal
canine bone was provided by the Comparative Orthopedics
Research Laboratory at the University of Wisconsin-Madison
School of Veterinary Medicine.
Cell lines were generated from the tumor tissue of dogs
undergoing amputation for treatment of OSA at the UWVMTH.
Patient requirements for inclusion into this study included no
treatment with corticosteroids for a period of two weeks preceding
the identification of increased serum alkaline phosphatase
concentration and tissue collection, histological confirmation of
OSA, and liver enzyme values within normal limits with the
exception of alkaline phosphatase.
The determination of serum alkaline phosphatase concentration
for patient samples utilized in this study occurred at multiple
reference laboratories and at different times. Therefore, the
normal reference ranges for serum alkaline phosphatase concen-
trations differed based on the reporting institute. For this reason
each patient was classified as having normal or increased serum
alkaline phosphatase according to the normal reference value
range for that institute at the time of sampling. The reference
ranges provided by institutions were as follows: 13–289, 20–157,
and 20–142 U/L.
Cell culture
Primary cell lines were generated from clinical tissue samples.
Tumor tissue was surgically excised, placed on ice, and stored in
phosphate-buffered saline (PBS) with PenStrepFungizone (Invitro-
gen, CA) to prevent microbial contamination. Mechanical and
enzymatic digestion using collagenase I (200 units/ml) and DNase
I (100 units/ml) was used in association with scalpel and scissors
mincing, followed by filtration through a 40 mesh sieve until a
single cell suspension was created. The resulting cell suspension
was centrifuged for 7 min at 1400rpm. The pellet is then washed
with sterile saline and re-centrifuged with the same conditions. To
the pellet, 3 mL of complete modified eagle media (CMEM) is
added, and the mixture is incubated in a flask with an additional
9 mL of CMEM. All cells were maintained in CMEM: MEM
medium supplemented with 10% heat-inactivated cosmic calf
serum, sodium pyruvate, l-glutamine, MEM vitamins, non-
essential amino acids, and 1% Pen/Strep at 37uC in a humidified
incubator with 5% CO2. All cell lines used in this experiment were
beyond the 15
th passage.
Quantitative PCR (qPCR)
Total RNA was isolated from clinical samples using Trizol
(Invitrogen,Carlsbad, CA), and purified byPureLink RNA Mini Kit
(Ambion, Life Technologies, Carlsbad, CA) according to the
manufacturer’s instructions. cDNA was synthesized from 250 ng of
total RNA using the High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems,Life Technologies, Carlsbad CA) according
to the manufacturers protocol. qPCR was performed using TaqMan
GeneExpressionMasterMixwithTaqManGeneExpressionAssays
(Applied Biosystems, Life Technologies, Carlsbad CA) according
to the manufacters protocol on a Bio-Rad iCycler machine with
a Bio-Rad iQ5 Multicolor Real-Time PCR Detection System.
Assays include: canine b-catenin (Cf02667771_m1), canine Axin2
(Cf02631333_m1), and human SOX9 (Cf02631333_m1) (Applied
Biosystems, Life Technologies, Carlsbad, CA). Ct values were
normalized to 18S expression (4352930E). Relative difference in
mRNA expression of clinical OSA samples was compared to normal
canine bone obtained from the Comparative Orthopaedic Research
Laboratory, School of Veterinary Medicine, University of Wisconsin
– Madison, using the DDCt method [35]. Gene expression of
samples was measured in triplicate.
Tissue cell lysate
Total cell lysates of ten clinical canine OSA samples (increased
serum ALP n=5 or normal serum ALP n=5) were obtained by
combining approximately 250–500 mg of tissue and 1 mL of
Mammalian Protein Extraction Reagent (M-PER) in a 15 mL
tissue grinder. Included samples were randomly chosen from the
same patient population used for QPCR analysis. Tissue was
ground until lysate appeared homogenous (5–10 min), then
centrifuged for 7.5 min at 13,000rpm at 4uC. Lysates were stored
at 220uC. Pooled increased serum ALP or normal serum ALP
lysates were formed by combining 200 mg of protein lysate from
each single sample.
Fractionated cell lysate
Nuclear fractions of two primary cell line lysates (increased
serum ALP, iALPOS, and normal serum ALP, nALPOS) were
isolated using the Subcellular Protein Fractionation Kit (Pierce
Biotechnology, Rockford, IL). Manufacturers protocol was used to
isolate membranous and cytoplasmic fractions; the remaining
Wnt Activity Does Not Correlate with ALP in OSA
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stored at 220uC.
Western Blotting Analysis
Forty micrograms of protein lysate (total and nuclear) were
separated by electrophoresis on a 7.5% sodium dodecyl sulphate-
polyacrylamide gel at 150 V for 45 min, transferred to nitrocel-
lulose membranes at 100 V for 1 h, then blocked with tris-
buffered saline/0.05% Tween20 (TBST) containing 5% non-fat
dry milk and 1% bovine serum albumin for 1 h. The membranes
were probed for overnight at 4uC with either (a) mouse anti-b-
catenin antibody (#610154, BD Biosciences, Bedford, MA)
diluted 1:1000 in blocking solution, (b) goat anti-GAPDH (sc-
20357, Santa Cruz Biotechnology, Santa Cruz, CA) diluted 1:200
in blocking solution, or (c) rabbit anti-laminin (ab11575, Abcam
Inc, Cambridge, MA) diluted 1:200 in blocking solution. Excess
primary antibody was removed by washing three times for 5 min
with TBST. Membranes were incubated with 50 ng/mL horse-
radish peroxidase-conjugated secondary antibody diluted in
blocking solution for 1 h at room temperature, then washed three
times for 5 min at TBST, and treated with SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientific, Pierce Biotech-
nology, Rockford, IL). Blots were exposed to film, developed, and
then imaged using a Gel Logic 100 Imaging System (Kodak,
Rochester, NY).
Luciferase Reporter Assay for Wnt/b-catenin activity
Cell lines were plated in a six-well plate at a density to achieve
40–50% confluency within 24 h. Cells were then transiently
transfected using Lipofectamine LTX and PLUS reagents
(Invitrogen, Carlsbad CA), according to the manufacturers
protocol, to introduce either 2.5 mg TOPflash, or 2.5 mg FOPflash
reporter plasmid, along with 0.5 mg of TK-Renilla luminescent
reporter plasmid (TCF Reporter Plasmid Kit, Millipore, Teme-
cula, CA). The TOPflash luciferase reporter plasmid contains
TCF4 binding sites upstream of the luciferase gene, resulting in
luciferase activity in the presence of active Wnt/b-catenin
signaling, whereas the FOPflash reporter plasmid contains
mutated TCF4 binding sites. The TK-Renilla plasmid serves as
a control for transfection efficiency. Twenty-four hours after
transfection, cells were harvested and luciferase and renilla
luminescence were measured using the Dual-Luciferase Reporter
Assay System (Promega, Madison, WI) on a luminometer (BioTek
Synergy HT Multi-mode Microplate Reader, and Gen5 software;
BioTek Instruments, Winooski, VT). The relative luciferase units
for each transfection were adjusted by renilla activity in the same
sample, and each corrected TOPflash luciferase value was
normalized to the corresponding corrected FOPflash value. Three
independent transfections were performed, with each sample
assayed in triplicate.
Immunohistochemistry
Immunohistochemical staining (IHC) was performed on slides
made from archived osteosarcoma tissue to detect b-catenin
protein. The process of b-catenin IHC staining and quantification
of staining was performed as previously published [36]. Briefly,
one investigator (AM), who was blinded to whether IHC-stained
slides were from patients with normal or increased serum ALP,
quantified the percentage of positively-staining tumor cells and
characterized the intensity of positively-stained slides as mild,
moderate or strong. Numerical values were applied to the
percentage of positively-labeled cells and staining intensity with
the overall staining score being the product of these two scores.
Slides were imaged using a Nikon Eclipse TE2000-U microscope
(Nikon Eclipse TE2000-U microscope with a Nikon Digital
Camera DXM1200F using NIS-Elements F2.30 software).
Statistical Analysis
All statistical comparisons were performed using a Mann
Whitney Test with commercially-available software (Prism5,
GraphPad Software, La Jolla, CA); p,0.05 was considered
significant. All data are given as the median and range of values
unless otherwise indicated. To determine the correlation between
QPCR target gene expression and serum ALP concentration a
linear regression analysis was performed using the same commer-
cially-available software. R
2 values and p values are reported.
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